LNTH Lantheus Holdings Inc

Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR

Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR

PYLARIFY success leads to maximum payment in first year

BEDFORD, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced that it has instructed the rights agent to distribute $99.7 million to the holders of Contingent Value Rights (CVRs), which were issued in conjunction with Lantheus’ acquisition of Progenics Pharmaceuticals, Inc. on June 19, 2020.

Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum amount allowed to be paid. As a result of the net sales generated by PYLARIFY in 2022, the maximum aggregate cash payment of $99.7 million is being distributed to the holders. This is the first and final payment related to the CVRs and is in full satisfaction of Lantheus’ payment obligations related to the CVRs.

If your CVRs are held with your broker, please contact your broker for information specific to your holdings. If your CVRs are held at the rights agent, Computershare Trust Company, N.A., please contact Computershare for information specific to your holdings. Holders of CVRs should consult their tax advisor as to the tax treatment of the CVRs.

About Lantheus

With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit .

Contacts:

Mark Kinarney

Vice President, Investor Relations

978-671-8842

Melissa Downs

Senior Director, Corporate Communications

646-975-2533



EN
23/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18...

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater patient availability PYLARIFY TruVu™ is expected to launch in 4Q 2026, with a phased geographic rollout to support a seamless customer transition BEDFORD, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to en...

 PRESS RELEASE

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate ...

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA® BEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has received U.S. Food and Drug Administration (FDA) tentative approval for the Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent1 version o...

 PRESS RELEASE

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results a...

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that ...

 PRESS RELEASE

Lantheus to Present at March 2026 Investor Conferences

Lantheus to Present at March 2026 Investor Conferences BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Executive Chairperson and Chief Executive Officer, will present at the following investor conferences. TD Cowen 46th Annual Health Care ConferenceMarch 3, 2026 at 11:10 a.m. ETLeerink Global Healthcare ConferenceMarch 10, 2026 at 8:00 a.m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch